Alzheimer insights: Anti-amyloid safety and tau takeaways, a BioCentury podcast

Plus: FDA & the election and state of play for China biotech 

It’s too soon to conclude anti-amyloid therapies are safe for use by Alzheimer’s patients in the real world, even as early reports are encouraging, argues BioCentury Executive Editor Selina Koch on the latest BioCentury This Week podcast. Koch and colleagues discuss takeaways from this year’s Clinical Trials on Alzheimer’s Disease annual meeting, including conclusions from adverse event data for Leqembi lecanemab and what the true test of appropriate use and safety for the drug might look like.

BioCentury’s editors also assess Phase II data presented at CTAD by UCB S.A. (Euronext:UCB) that provide some of the first clues about what species of tau to target and in which patients. And they discuss what results of Tuesday’s presidential contest in the U.S. will mean for FDA, as well as the state of play for China biotech as the industry continues to grind out its first bear market.

For information on opportunities to sponsor The BioCentury Show and the BioCentury This Week podcast, please email conferences@biocentury.com. To submit a question to BioCentury’s editors, email the team at podcasts@biocentury.com.